4.8 Article

Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications

Journal

BIOMATERIALS
Volume 30, Issue 12, Pages 2349-2360

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2008.12.083

Keywords

Biodegradable; Thermosensitive; Hydrogel; Polymer-drug conjugate; Paclitaxel; Antitumor activity

Funding

  1. Ministry of Science and Technology in Korea [F104AA010007-07A0101-00110]
  2. National Research Council of Science & Technology (NST), Republic of Korea [2E21240] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
  3. National Research Foundation of Korea [2006-2008324] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

A poly(organophosphazene)-PTX conjugate was synthesized by a covalent ester linkage between M and carboxylic acid-terminated poly(organophosphazene), which can be readily modified by various hydrophobic, hydrophilic, and other functional substitutes. The physicochemical properties, hydrolytic degradation and PTX release behaviors of the polymer-PTX conjugate were characterized, in addition to the in vitro and in vivo antitumor activities. The aqueous solutions of these conjugates showed a sol-gel transition behavior that depended on temperature changes. The in vitro antitumor activity of the polymer-M conjugate was investigated by an MTT assay against human tumor cell lines. From the in vivo antitumor activity studies with tumor-induced (xenografted) nude mice, the polymer-paclitaxel conjugate hydrogels after local injection at the tumor site were shown to inhibit tumor growth more effectively and longer than paclitaxel and saline alone, indicating that the tumor-active paclitaxel from the polymer-PTX conjugate hydrogel is released slowly over a longer period of time and effectively accumulated locally in the tumor sites. These combined observations suggest that this poly (organophosphazene)-PTX conjugate holds promise for use in clinical studies as single and/or combination therapies. (C) 2009 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available